Navigation Links
Anti-tumor therapy with endoscopic ultrasound may fight cancer more safely and effectively
Date:9/12/2008

SAN FRANCISCO, CA, September 12, 2008 - The chairman of EUS2008 today announced that investigational research on a therapeutic technique that will allow physicians to directly inject malignant tumors with cancer fighting agents from inside the body will be presented at the 16th International Symposium of Endoscopic Ultrasonography (EUS2008) in San Francisco on September 12-13. This technique, which uses a flexible gastrointestinal endoscope with a miniature ultrasound transducer on the tip to guide a small needle directly into a tumor, could prove to be a safer and more effective approach to administering chemotherapy since it allows doctors to deliver therapy right to the tumor and avoid damaging normal surrounding tissues. Injecting drugs directly into the cancer using endoscopic ultrasound (EUS) in combination with systemic chemotherapy to kill cancer cells that have spread may prove to be a more effective approach to some cancers.

EUS combines endoscopy and ultrasound in order to obtain the most accurate, high resolution images and information about the digestive tract and the surrounding tissue and organs. A more advanced form of EUS, called curvilinear EUS, allows doctors to operate within the lumen of the gut while at the same time detect, biopsy and treat lesions and tumors that lie outside the intestinal wall. This technique is particularly useful in patients with pancreatic, esophageal and rectal cancer.

"Curvilinear endosonography will likely become the dominant technology within the field of EUS," said co-chairman of EUS2008, Robert Hawes, M.D., Professor of Medicine and Peter Cotton Chair for Endoscopic Innovation at the Medical University of South Carolina. "The potential for accurate diagnosis using ultrasound-guided biopsy, precise staging with high resolution ultrasound images and then the enormous opportunity for new therapies with the curvilinear endoscope is why we are focusing this meeting on the use of this instrumen
'/>"/>

Contact: Lisa Koen
lkoen@golinharris.com
212-373-6099
Golin/Harris International
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Eribulin mesylate demonstrated anti-tumor activity in patients with advanced breast cancer
2. A new radiation therapy treatment developed for head and neck cancer patients
3. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
4. UC health news: molecular pathway may predict chemotherapy effectiveness
5. MIT works toward safer gene therapy
6. Intravenous gene therapy protects normal tissue of mice during whole-body radiation
7. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
8. Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases
9. Safe and effective therapy discovered for patients with protein-losing enteropathy
10. Ireland Cancer Center researchers advance stem cell gene therapy
11. Dolphin therapy a dangerous fad, Emory researchers warn

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Anti-tumor therapy with endoscopic ultrasound may fight cancer more safely and effectively
Anti-tumor therapy with endoscopic ultrasound may fight cancer more safely and effectively
(Date:11/4/2009)...g Beach and Riverside are responsible for a signif...and the true impact of air pollution and ship emis...d, according to researchers at the University of S...pears in an online edition of the American Journa...f all childhood asthma cases in Long Beach and six...
(Date:11/4/2009)... DNA codes, or genomes, of the famed fugu (or puff...10K Project, an international effort to build an i...ecies of animals for conducting comparative studie..., Participating in The Genome 10K project, descri... of the Journal of Heredity , are 70 leading scie...
(Date:11/4/2009)...Call/ -- Quest Diagnostics Incorporated (NYSE: DG...sting, information and services, announced that fo...me from continuing operations rose to $192 million...r $0.81 per diluted share, for the third quarter o...d by a $0.03 per share charge associated with the ...
Breaking Biology News(10 mins):USC study finds big air pollution impacts on local communities 2Singapore scientists join international study of 10,000 vertebrates' genomes 2Quest Diagnostics Reports Strong Performance in Third Quarter 2009 2Quest Diagnostics Reports Strong Performance in Third Quarter 2009 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 4Quest Diagnostics Reports Strong Performance in Third Quarter 2009 5Quest Diagnostics Reports Strong Performance in Third Quarter 2009 6Quest Diagnostics Reports Strong Performance in Third Quarter 2009 7Quest Diagnostics Reports Strong Performance in Third Quarter 2009 8Quest Diagnostics Reports Strong Performance in Third Quarter 2009 9Quest Diagnostics Reports Strong Performance in Third Quarter 2009 10Quest Diagnostics Reports Strong Performance in Third Quarter 2009 11Quest Diagnostics Reports Strong Performance in Third Quarter 2009 12Quest Diagnostics Reports Strong Performance in Third Quarter 2009 13Quest Diagnostics Reports Strong Performance in Third Quarter 2009 14Quest Diagnostics Reports Strong Performance in Third Quarter 2009 15Quest Diagnostics Reports Strong Performance in Third Quarter 2009 16Quest Diagnostics Reports Strong Performance in Third Quarter 2009 17NIH recognizes engineering professors innovative research with major award 58789 1NIH recognizes engineering professors innovative research with major award 58789 2NIH recognizes engineering professors innovative research with major award 58789 3Einstein to develop anti HIV drug delivery system 10245 1Einstein to develop anti HIV drug delivery system 10245 2Einstein to develop anti HIV drug delivery system 10245 3ADA Culminates Yearlong 150th Anniversary Observance at Its 150th Annual Session 58785 1ADA Culminates Yearlong 150th Anniversary Observance at Its 150th Annual Session 58785 2ADA Culminates Yearlong 150th Anniversary Observance at Its 150th Annual Session 58785 3
...ry 1st issue of G&D, Drs. Thomas Mullen and Willia... the degradation of mammalian histone,mRNA. Histo... but the,mechanism by which this occurs has remain...e, conserved 3, stem-loop structure rather than th...ff demonstrate that uridine,residues are added to ...
...c. 28, 2007) -- A research team at Weill Cornell M... genes that may be crucial to the production of an...10). , The discovery fills in an important "mis...en tied to disorders ranging from lupus and Type 1...n has to be kept in a delicate balance for health,...
...deep-sea species poses a severe threat to the futu... early online on December 27th and in the January ...l Press. In a global-scale study, the researchers ...f the deep sea, as measured by the rate of critica...h the diversity of species living there. , For th...
Other Biology News:2 genes are important key to regulating immune response 22 genes are important key to regulating immune response 3Deep-sea species' loss could lead to oceans' collapse, study suggests 2
(Date:11/6/2009)...Newswire/ -- EUCODIS Bioscience, a company,develop...ymes for the,chemical industry announced today tha...o Sidus, the leading biopharmaceutical company in ...DIS Bioscience exclusive access - for the search,o...collection of,psychrophilic bacteria strains and o...
(Date:11/6/2009)...Arrowhead’s 2010 Personalized Medicine Partn...February 22-24, 2010 in Philadelphia, has been ann...ight key issues in forming partnerships and engage... Minneapolis, MN (PRWEB) No... 2010 Personalized Medicine Partnerships Conferen...
(Date:11/5/2009)...Call/ -- Imagenetix, Inc. (OTC Bulletin Board: IAG...t and CEO of Imagenetix, will be presenting the Co...e on Thursday, December 3rd, at 10:30 AM PST at th... ,, LD MICRO is a by-invitation only newsletter...s in the micro-cap space. Since 2002, the firm has...
(Date:11/5/2009)...re-FirstCall/ -- Cepheid (Nasdaq: CPHD ) today an...e following investor conferences, and invited inve... Credit Suisse Healthcare Conference, Phoenix, ... 10 a.m. Mountain Time, NASDAQ OM... Tuesday, 1 December, 2009 at 10.45 a.m. Gr...
Breaking Biology Technology:EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Cepheid to Webcast Upcoming Financial Presentations 2
...h 13 ,Cellectis SA (NYSE: ALCLS ), a world leader...y that it filed a patent infringement lawsuit agai...es District Court for the,Eastern District of Nort...y making and selling certain meganucleases, Precis...lating to its proprietary meganuclease,recombinati...
.../ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI ...,medical device company, today announced the filin... and Management,s Discussion and Analysis,for the ...f its audited,consolidated financial statements fo... ended December 31, 2007, the Company,s net loss a...
...c.,(Nasdaq: BNVI ) announced today the appointmen...of Directors. Dr. Butler has extensive regulatory,...es, and in particular in,advancing cancer drug dev...d to have George on board as we move into a new,ph...linical trial,programs," said Isaac Cohen, O.M.D.,...
Other Biology Technology:Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology 2Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology 3Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology 4Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 2Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 3Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 4Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 5Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 6Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 7Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 8Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 9George Butler Joins Bionovo's Board of Directors 2George Butler Joins Bionovo's Board of Directors 3
...ular Localization Kit with TransIT-siQUEST Transfe... to directly label and deliver siRNA, of your desi...r in vitro tracking experiments. Subcellular local...xpression can be monitored following introduction ...
...atrix (ECM) is an important step in tumor metastas... and spreading along the blood vessel wall. Prote... tiny holes in the sheath-like covering (basement ...ancer cells to invade.,The CHEMICON Cell Invasio...
Corning Cryo Box, 81 Position, 4-5 ml, Non-Sterile from Sigma-Aldrich
MACS Protein A/G Starting Kit from Miltenyi Biotec
Biology Products: